Search

Displaying results 7211 - 7220 of 7654 in total
  1. Drug

    Tymazoline

    go.drugbank.com/drugs/DB08803
    Experimental

    Tymazoline is a nasal preparation.

  2. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)

  3. Drug

    Lactobacillus plantarum

    go.drugbank.com/drugs/DB11360
    Investigational

    It is considered to be one of versatile species that carry out fermentative and metabolic processes, while exhibiting an antagonistic activity against pathogenic and spoilage microorganisms.

  4. Drug

    XMT-1001

    go.drugbank.com/drugs/DB06069
    Investigational

    XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models

  5. Drug

    Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen

    go.drugbank.com/drugs/DB16517
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/South Australia/55/2014 live (attenuated) antigen

    go.drugbank.com/drugs/DB16518
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB16718
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16720
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16722
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen